Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Disease-Specific Validation of the revised Utah Photophobia Symptom Impact Scale in Migraine Subjects
Headache
Headache Posters (7:00 AM-5:00 PM)
060
Migraine headache affects one in six Americans,1-2 and is considered the “most common disabling brain disorder.”3 Photophobia (abnormal sensitivity to light) is included as a major diagnostic criterion for migraine headache4 and is reported by up to 80% of migraine patients.5 Our group previously developed a new questionnaire (the Utah Photophobia Symptom Impact Scale; UPSISv1) to measure the impact of light sensitivity on activities of daily living, and statistically validated it using Rasch analysis and quantitative interictal light sensitivity testing.8 We have since revised this version to improve internal consistency, and provide additional clinical validation.10
NA
Patients were screened in the Headache and Neuro-ophthalmology clinic at the University of Utah for recurrent headaches, and invited to participate in a consent-exempt questionnaire-based symptom assessment. All patients completed the revised Utah Photophobia Symptom Impact Scale (UPSISv2), Headache Impact Test (HIT-6), Migraine Disability Assessment Test (MIDAS), and a structured questionnaire to phenotype headache diagnosis based on International Classification of Headache Disorders-3 criteria. Association between UPSISv2 and clinical migraine-severity scores were assessed using Spearman’s rho; between group differences were assessed using t-testing (or nonparametric equivalent as appropriate)

A total of 109 surveys were completed (43 chronic migraine, 28 Episodic migraine, 25 Probable migraine, and 13 with non-migraine type headaches). The UPSISv2 positively correlated with the UPSISv1 (rho=.84; p<.001), HIT-6 (rho=0.58; p<.001) and MIDAS score (rho=0.58; p<.001). Mean UPSISv2 scores were significantly higher in Chronic Migraine subjects compared to non-migraine headache subjects (unpaired, two-sample t-test, p<.0001).

These data provide preliminary clinical validation of the revised UPSIS by demonstrating a strong correlation between related clinical measures of headache severity. Follow-up Rasch analysis and confirmation of statistical validation of the UPSISv2 will provide a robust, well-validated tool for clinical and research-based assessment of patient-reported photophobia and the impact of these symptoms of daily life.
Authors/Disclosures
Alexander Knudson
PRESENTER
Alexander Knudson has nothing to disclose.
Cecilia Martindale Cecilia Martindale has nothing to disclose.
Melissa M. Cortez, DO (University of Utah Neurology) The institution of Dr. Cortez has received research support from NIH NINDS. The institution of Dr. Cortez has received research support from Amgen Independent Investigator Award. Dr. Cortez has received personal compensation in the range of $500-$4,999 for serving as a Content Expert, Reviewer, DSMB with NIH RECOVER project.
Bradley J. Katz, MD, PhD Bradley J. Katz, MD, PhD has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for axon optics, LLC. Bradley J. Katz, MD, PhD has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for self employed. Bradley J. Katz, MD, PhD has received stock or an ownership interest from Pfizer. Bradley J. Katz, MD, PhD has received intellectual property interests from a discovery or technology relating to health care.
Kathleen B. Digre, MD, FAAN (University of Utah) Dr. Digre has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for American Headache Society. The institution of Dr. Digre has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Neuro-ophthalmology. The institution of Dr. Digre has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Utah Womens Health Review. Dr. Digre has received intellectual property interests from a discovery or technology relating to health care. Dr. Digre has received intellectual property interests from a discovery or technology relating to health care. Dr. Digre has received intellectual property interests from a discovery or technology relating to health care. Dr. Digre has received publishing royalties from a publication relating to health care. Dr. Digre has received publishing royalties from a publication relating to health care.